In turn, Karnevi provided molecular evidence that the decreased anticancer action of metformin in pancreatic cancer cells exposed to HG involved the insulin/insulin-like growth factor-1 (IGF1) pathway. This evidence concerns the gene IGF1 and pancreatic neoplasm.